AAMI and TechNation Collaborate to Survey HTM Field
Survey will assess demographics, salary rates, moreArlington, Virginia, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Soon, the health technology community will...
Healthcare
OneMedNet Welcomes Our Latest Subscriber mlHealth360
MINNEAPOLIS, Oct. 20, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq:ONMD) (“OneMedNet” or the “Company”), a leader in AI-powered Real-World Data...
PetMed Express, Inc. Appoints Former Deloitte Partner James LaCamp as Director and Audit Committee Chair
Seasoned corporate director brings extensive expertise in audit, accounting, and internal controls Fourth independent director to join the board since...
NewGen Announces Strategic Entry into Art Tokenization Market with $2 Million Private Collection Deal, Expandable to $200 Million
BANGKOK, Oct. 20, 2025 (GLOBE NEWSWIRE) -- NewGenIvf Group Limited (Nasdaq: NIVF) (“NewGen” or the “Company”), a tech-forward, diversified, multi-jurisdictional...
Abeona Therapeutics® Appoints James A. Gow, MD, MBA, MS, MHCM, as Senior Vice President, Head of Clinical Development & Medical Affairs
CLEVELAND, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing cell and gene...
Oscar Unveils New Choices and AI Tools Shaping the Future of Individual Healthcare for More Americans and Businesses
NEW YORK--(BUSINESS WIRE)--Oscar Health, Inc. (NYSE: OSCR), a leading healthcare technology company, is introducing a suite of easy-to-use health plans...
ESMO releases first-ever guidance for safe use of AI Language Models in cancer care
The ELCAP guidance sets standards for responsible AI use in oncology, protecting patients and supporting clinicians LUGANO, Switzerland and BERLIN,...
Peer-Reviewed Journal of Clinical Psychiatry Publishes Mentavi’s Online ADHD Diagnostic Evaluation Validation Study
Open-access publication demonstrates the validity and reliability of the Mentavi online Diagnostic Evaluation compared to a clinical interview, widening evidence...
Genflow Biosciences PLC Announces Recognition of Patentability of Claims
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET...
HDAI to announce AI tools that drive quality outcomes at HLTH 2025
LAS VEGAS, Oct. 19, 2025 /PRNewswire/ -- Nassib Chamoun, CEO of Health Data Analytics Institute (HDAI), a leader in enterprise risk...
Moderna Highlights Seasonal Flu and H5 Pandemic Flu Candidates at IDWeek 2025
CAMBRIDGE, MA / ACCESS Newswire / October 19, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced data regarding two of its...
Replimune Highlights Acral Melanoma Data for RP1 plus Nivolumab at the ESMO Congress 2025
WOBURN, Mass., Oct. 19, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the...
Biden’s DEA Wall of Marijuana Dishonor: The DEA Pattern of Corruption Is Now Impossible to Deny, President Trump Fixing
Now, President Trump is poised to fix the marijuana rescheduling issue.From DEA unconstitutional tribunals to Anne Milgram swamp contracts and...
Detailed Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial Presented at 2025 ESMO Congress Demonstrate Potential for Gedatolisib Regimens to be Practice Changing for Patients with HR+/HER2- Advanced Breast Cancer
Clinical benefit of the gedatolisib regimens was consistent across patient subgroups Hyperglycemia was reported in only 9.2% of patients treated with...
Celcuity Presents Updated Data at the 2025 ESMO Congress from Phase 1 Study Evaluating Gedatolisib Plus Darolutamide in Men with Metastatic Castration Resistant Prostate Cancer (“mCRPC”)
Median radiographic progression free survival (“rPFS”) was 9.1 months and the six-month rPFS rate was 67% No patients discontinued study...
Celcuity Provides Update on Status of the PIK3CA Mutated Cohort of Phase 3 VIKTORIA-1 Trial and Releases Additional Data Analysis From Phase 1b Clinical Trial
PIK3CA mutant cohort of the Phase 3 VIKTORIA-1 clinical trial is fully enrolledAdditional analysis of data from a Phase 1b...
Roche’s phase III evERA data showed giredestrant significantly improved progression-free survival in people with ER-positive advanced breast cancer
Giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1-mutated populations,...
Desert Oasis Healthcare and RadNet Partner to Advance Early Breast Cancer Detection
Program will increase access to cutting-edge AI-powered breast cancer detection and is designed to boost compliance with annual cancer-screening guidelines...
UniDoc Announces Amended LIFE Offering
THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BC...
Inception Fertility Commends President Trump for Encouraging Employers to Expand Fertility Benefits
In a press conference, the President called on US employers to expand healthcare benefits to include IVF HOUSTON, Oct. 17,...